Jd. Sobel et al., SINGLE ORAL DOSE FLUCONAZOLE COMPARED WITH CONVENTIONAL CLOTRIMAZOLE TOPICAL THERAPY OF CANDIDA-VAGINITIS, American journal of obstetrics and gynecology, 172(4), 1995, pp. 1263-1268
OBJECTIVES: Candida vaginitis is currently treated with a wide range o
f intravaginal preparations usually prescribed over several days. Fluc
onazole with its marked activity against Candida species and favorable
pharmacokinetics offered a safe, effective, and convenient alternativ
e to topical therapy in a single-dose regimen. STUDY DESIGN: We conduc
ted a multicenter, randomized, prospective, single-blinded study of 42
9 patients with acute Candida vaginitis, comparing the efficacy and sa
fety of a single oral 150 mg dose of fluconazole with 7-day clotrimazo
le 100 mg vaginal treatment. Posttherapy evaluations and mycologic era
dication rates were conducted. RESULTS: No statistically significant d
ifferences were seen between fluconazole and clotrimazole in the clini
cal, mycologic, or therapeutic responses. At the 14-day evaluation cli
nical cure or improvement was seen in 94% of fluconazole-treated patie
nts and 97% of clotrimazole-treated patients. Mycologic and therapeuti
c cures were seen in 77% and 76% of the fluconazole and 72% of the clo
trimazole groups, respectively. At the 35-day evaluation 75% of both g
roups remained clinically cured, and 56% of the fluconazole and 52% of
the clotrimazole group were considered therapeutic cures. In both tre
atment groups patients with a history of recurrent vaginitis (33/84) c
ompared with those without a history of recurrent vaginitis (177/266)
were significantly less likely to respond clinically and mycologically
(p < 0.001). Twenty-seven percent of the fluconazole-treated patients
and 17% of the clotrimazole-treated patients reported mild side effec
ts only. CONCLUSION: Fluconazole administered as a single 150 mg oral
dose proved to be as safe and effective as 7 days of intravaginal clot
rimazole therapy for Candida vaginitis. Therapy of vaginitis should be
individualized, taking into consideration severity of disease, histor
y of recurrent vaginitis, and patient preference.